DR info

Clinical trials : 11 / Drugs : 6 - (DrugBank : 1) / Drug target gene : 1 - Drug target pathways : 44

Drugs and their primary sponsors and trial info

ACZ885
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-004291-35-IT   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A.
      2014   Phase 3   EUCTR2013-004291-35-ES   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-NL   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-IE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-HU   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-GR   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-BE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
ACZ885, 150mg/1.0ml
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-DE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Canakinumab
   Novartis Pharmaceuticals
      2011   Phase 2   NCT01303380   Spain;
ITF2357
   Radboud University
      2006   Phase 2   NCT00442182   Netherlands;
Ilaris
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-004291-35-IT   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A.
      2014   Phase 3   EUCTR2013-004291-35-ES   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-NL   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-DE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan;